These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 14597580)

  • 1. Endothelin receptor blockers in cardiovascular disease.
    Rich S; McLaughlin VV
    Circulation; 2003 Nov; 108(18):2184-90. PubMed ID: 14597580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
    Barst RJ; Langleben D; Badesch D; Frost A; Lawrence EC; Shapiro S; Naeije R; Galie N;
    J Am Coll Cardiol; 2006 May; 47(10):2049-56. PubMed ID: 16697324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
    Benza RL; Mehta S; Keogh A; Lawrence EC; Oudiz RJ; Barst RJ
    J Heart Lung Transplant; 2007 Jan; 26(1):63-9. PubMed ID: 17234519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
    Cacoub P; Amoura Z; Langleben D
    Rev Med Interne; 2008 Apr; 29(4):283-9. PubMed ID: 18243424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade.
    Langleben D; Cacoub P
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
    Hoeper MM
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension.
    Wilkins MR
    Am J Respir Crit Care Med; 2004 Feb; 169(4):433-4. PubMed ID: 14766656
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
    Steiner MK; Preston IR
    Vasc Health Risk Manag; 2008; 4(5):943-52. PubMed ID: 19183742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Dupuis J; Hoeper MM
    Eur Respir J; 2008 Feb; 31(2):407-15. PubMed ID: 18238950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects.
    Mehta PK; Simpson L; Lee EK; Lyle TA; McConnell ME; Book WM
    Tex Heart Inst J; 2008; 35(3):256-61. PubMed ID: 18941642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective and mixed endothelin receptor antagonism in cardiovascular disease.
    Dhaun N; Pollock DM; Goddard J; Webb DJ
    Trends Pharmacol Sci; 2007 Nov; 28(11):573-9. PubMed ID: 17950470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
    Shetty N; Derk CT
    Inflamm Allergy Drug Targets; 2011 Feb; 10(1):19-26. PubMed ID: 21184655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.
    Waxman AB
    Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
    Jacobs A; Preston IR; Gomberg-Maitland M
    Curr Med Res Opin; 2006 Dec; 22(12):2567-74. PubMed ID: 17166339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Langleben D
    Clin Chest Med; 2007 Mar; 28(1):117-25, viii. PubMed ID: 17338931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension.
    Opitz CF; Ewert R
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():1-9. PubMed ID: 16919004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study.
    Langleben D; Hirsch AM; Shalit E; Lesenko L; Barst RJ
    Chest; 2004 Oct; 126(4):1377-81. PubMed ID: 15486408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.
    Barst RJ; Rich S; Widlitz A; Horn EM; McLaughlin V; McFarlin J
    Chest; 2002 Jun; 121(6):1860-8. PubMed ID: 12065350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Updated treatment of primary pulmonary hypertension -- the role of endothelin receptor antagonists].
    Callejas Rubio JL; Ortego Centeno N; Navarro Pelayo F; Vallejo Rodríguez I
    Farm Hosp; 2004; 28(4):294-5. PubMed ID: 15369441
    [No Abstract]   [Full Text] [Related]  

  • 20. Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension.
    Widlitz AC; Barst RJ; Horn EM
    Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):985-91. PubMed ID: 16292989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.